Welcome to our dedicated page for Puretech Health SEC filings (Ticker: PTCHF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Puretech Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Puretech Health's regulatory disclosures and financial reporting.
PureTech Health plc ownership disclosure: Tang Capital Management, LLC and affiliated filers report beneficial ownership of 12,635,782 Ordinary Shares, equal to 5.19% of the class. The statement cites 243,418,190 Ordinary Shares outstanding as of March 31, 2026 from the Month End Disclosure of Total Voting Rights and Share Capital filed with the London Stock Exchange on April 1, 2026.
The filing states the holders have shared voting and shared dispositive power over the reported shares, with the positions held jointly by Tang Capital entities and Kevin Tang.
PureTech Health plc ownership disclosure: Tang Capital Management, LLC and affiliated filers report beneficial ownership of 12,635,782 Ordinary Shares, equal to 5.19% of the class. The statement cites 243,418,190 Ordinary Shares outstanding as of March 31, 2026 from the Month End Disclosure of Total Voting Rights and Share Capital filed with the London Stock Exchange on April 1, 2026.
The filing states the holders have shared voting and shared dispositive power over the reported shares, with the positions held jointly by Tang Capital entities and Kevin Tang.
PureTech Health plc, a biotechnology company incorporated in England and Wales, has filed its annual report on Form 20-F for the year ended December 31, 2025. Its American Depositary Shares (each representing 10 ordinary shares) trade on the Nasdaq Global Market under the symbol PRTC.
The company focuses on therapeutic candidates within its Wholly-Owned Programs and a group of Founded Entities. As of December 31, 2025, it had never generated revenue from therapeutic candidates within its Wholly-Owned Programs and highlights that it may never be operationally profitable, emphasizing ongoing dependence on substantial additional funding.
The filing summarizes extensive risk factors typical for clinical-stage biotech, including clinical and regulatory uncertainty, potential safety issues, manufacturing challenges, intellectual property protection, reliance on third parties and collaborators, and significant volatility in the market price of its ADSs.
PureTech Health plc, a biotechnology company incorporated in England and Wales, has filed its annual report on Form 20-F for the year ended December 31, 2025. Its American Depositary Shares (each representing 10 ordinary shares) trade on the Nasdaq Global Market under the symbol PRTC.
The company focuses on therapeutic candidates within its Wholly-Owned Programs and a group of Founded Entities. As of December 31, 2025, it had never generated revenue from therapeutic candidates within its Wholly-Owned Programs and highlights that it may never be operationally profitable, emphasizing ongoing dependence on substantial additional funding.
The filing summarizes extensive risk factors typical for clinical-stage biotech, including clinical and regulatory uncertainty, potential safety issues, manufacturing challenges, intellectual property protection, reliance on third parties and collaborators, and significant volatility in the market price of its ADSs.
PureTech Health released its annual results for the year ended December 31, 2025 and outlined a more focused, capital‑efficient strategy built around its hub‑and‑spoke model. PureTech level cash, cash equivalents and short‑term investments were $277.1 million as of December 31, 2025, and management expects an operational runway at least through the end of 2028, including planned participation in Founded Entity financings.
The portfolio is led by Celea Therapeutics’ Phase 3‑ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology’s LYT‑200 for relapsed/refractory high‑risk myelodysplastic syndrome and acute myeloid leukemia, and Seaport Therapeutics’ clinical‑stage neuropsychiatric pipeline, which is pursuing an IPO via a filed Form S‑1. PureTech reported 2025 revenue of $4.7 million, largely from contract and royalty revenue, with general and administrative expenses of $46.6 million and research and development expenses of $56.6 million, resulting in a net loss attributable to owners of $109.7 million.
The company plans to house major programs in externally funded Founded Entities to lower central operating costs and reduce risk concentration, and it expects a significant reduction in operational burn after Celea’s planned financing closes. PureTech also intends to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading on the London Stock Exchange, aiming for a simpler structure and lower administrative cost while maintaining access to global investors.
PureTech Health released its annual results for the year ended December 31, 2025 and outlined a more focused, capital‑efficient strategy built around its hub‑and‑spoke model. PureTech level cash, cash equivalents and short‑term investments were $277.1 million as of December 31, 2025, and management expects an operational runway at least through the end of 2028, including planned participation in Founded Entity financings.
The portfolio is led by Celea Therapeutics’ Phase 3‑ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology’s LYT‑200 for relapsed/refractory high‑risk myelodysplastic syndrome and acute myeloid leukemia, and Seaport Therapeutics’ clinical‑stage neuropsychiatric pipeline, which is pursuing an IPO via a filed Form S‑1. PureTech reported 2025 revenue of $4.7 million, largely from contract and royalty revenue, with general and administrative expenses of $46.6 million and research and development expenses of $56.6 million, resulting in a net loss attributable to owners of $109.7 million.
The company plans to house major programs in externally funded Founded Entities to lower central operating costs and reduce risk concentration, and it expects a significant reduction in operational burn after Celea’s planned financing closes. PureTech also intends to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading on the London Stock Exchange, aiming for a simpler structure and lower administrative cost while maintaining access to global investors.
PureTech Health plc plans to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading of its equity on the London Stock Exchange, which will remain its primary listing venue. Each ADS represents the right to receive ten ordinary shares.
The company expects to file Form 25 on or about May 11, 2026, with delisting becoming effective ten days later and the last trading day for ADSs on Nasdaq expected on or about May 20, 2026. After delisting, PureTech anticipates its ADSs will trade over-the-counter via a sponsored Level 1 ADR program, with no immediate action required from ADS holders.
PureTech also intends to file Form 15F to deregister its securities and terminate its reporting obligations under the U.S. Exchange Act, with termination expected to become effective no later than 90 days after that filing, absent SEC objection.
PureTech Health plc plans to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading of its equity on the London Stock Exchange, which will remain its primary listing venue. Each ADS represents the right to receive ten ordinary shares.
The company expects to file Form 25 on or about May 11, 2026, with delisting becoming effective ten days later and the last trading day for ADSs on Nasdaq expected on or about May 20, 2026. After delisting, PureTech anticipates its ADSs will trade over-the-counter via a sponsored Level 1 ADR program, with no immediate action required from ADS holders.
PureTech also intends to file Form 15F to deregister its securities and terminate its reporting obligations under the U.S. Exchange Act, with termination expected to become effective no later than 90 days after that filing, absent SEC objection.